Epigenetic enzyme mutations as mediators of anti-cancer drug resistance-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Epigenetic enzyme mutations as mediators of anti-cancer drug resistance

Published:2022-03 Issue: Volume:61 Page:100821
ISSN:1368-7646
Container-title:Drug Resistance Updates
language:en
Short-container-title:Drug Resistance Updates

Author:

Chen Sihong,Zhao Yingxi,Liu Shougeng,Zhang Jiayu,Assaraf Yehuda G.,Cui Wei,Wang Lihui

Publisher

Elsevier BV

Subject

Pharmacology (medical),Infectious Diseases,Cancer Research,Pharmacology,Oncology

Reference190 articles.

1. Mechanisms of acquired tumor drug resistance;Aleksakhina;Biochim. Biophys. Acta Rev. Cancer,2019

2. Advanced technological tools to study multidrug resistance in cancer;Andrei;Drug Resist. Updat.,2020

3. Noncanonical functions of the polycomb group protein EZH2 in breast cancer;Anwar;Am. J. Pathol.,2021

4. PRC2 loss induces chemoresistance by repressing apoptosis in T cell acute lymphoblastic leukemia;Aries;J. Exp. Med.,2018

5. Epigenetic protein families: a new frontier for drug discovery;Arrowsmith;Nat. Rev. Drug Discov.,2012

Cited by 27 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeting JNK kinase inhibitors via molecular docking: A promising strategy to address tumorigenesis and drug resistance;Bioorganic Chemistry;2024-12

2. Discovery of Novel Non-nucleoside DOT1L^R231Q Inhibitors with Improved Pharmacokinetic Properties and Anti-lung Cancer Efficacy;Journal of Medicinal Chemistry;2024-09-10

3. DNMT3A loss drives a HIF-1-dependent synthetic lethality to HDAC6 inhibition in non-small cell lung cancer;Acta Pharmaceutica Sinica B;2024-09

4. Writers, readers, and erasers RNA modifications and drug resistance in cancer;Molecular Cancer;2024-08-30

5. Discovery of first-in-class DOT1L inhibitors against the R231Q gain-of-function mutation in the catalytic domain with therapeutic potential of lung cancer;Acta Pharmaceutica Sinica B;2024-08

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3